A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Summary

The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.

Timeline

Start

2019-10-16

Primary completion

2023-03-28

Completion

2023-11-29

Outcome

Missed primary endpoint

registry analysis (other test); Crizanlizumab 5 mg/kg; p = 0.0676; Hodges-Lehmann 45.98 (95% CI 23.50 to 65.36); Wilcoxon Sign Rank Test NCT03938454 ↗

Drugs

Indications